University of Texas Medical Branch at Galveston Investigates Spray that Inactivates SARS-CoV-2

May 21, 2020 | Coronavirus, COVID-19, Galveston National Lab, Healthcare Workers, Personal Protective Spray, SARS-CoV-2, University of Texas Medical Branch Galveston

University of Texas Medical Branch at Galveston Investigates Spray that Inactivates SARS-CoV-2

Recently, the University of Texas Medical Branch at Galveston collaborated with a Florida company called Clyra Medical Technologies, Inc. to investigate the firm’s proprietary copper iodine antimicrobial and antiviral product called Clyraguard.™ The study team uncovered promising results: the personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by SARS-CoV-2 actually appears to work—it successfully inactivates the COVID-19 virus. This testing was led by Dr. Slobodan Paessler, DVM, PhD.

TrialSite News offers a brief breakdown of this quite promising and fascinating breakthrough. Note, the vendor recently donated what is claimed to be an FDA Class I approved spray to a hospital in Naples, Florida—NCH Healthcare

What is the Clyraguard product?

Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19.

Is the product registered with the U.S. Food and Drug Administration (FDA)?

Yes. It is registered with the FDA as a Class I general purpose disinfectant, according to claims by the company

What are core features that make it potentially valuable on the market?

Apparently the product features an extremely high antimicrobial efficiency at 99.999% kill rate (complete inactivation), and the recent testing showcases it actually inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

Moreover, it is a clear, colorless and odorless product that has been tested extensively and found to be non-irritating, non-sensitizing, non-toxic and non-staining.

Clyra Medical on their gratitude to Galveston National Lab

Steve Harrison, president of the company, commented, “Dr. Paessler and his team at the Galveston National Lab are experts in this area and the entire organization is highly responsive to help identify solutions in the time of crisis.”

More on Clyra Medical

With a headquarter office in Tampa, Florida, Clyra Medical is an innovative patent-protected copper iodine complex chemistry based on combining compounds that create a gentle but effective oxidative reaction. This reaction is effective against a wide range of organisms that cause disease pathogens. Organisms include viruses, fungi, spores, and antibiotic-resistant strains of bacteria. The company reports the product to be safe, effective, bio-compatible and cost-effective.

Founded in 2012, the company’s leadership evidences a seasoned leadership. The company is subsidiary of BioLargo, a Westminster California-based company. The subsidiary (Clyra) has few employees.

University of Texas Medical Branch & Galveston National Lab: Elite Highly Secure Research

The University of Texas Medical Branch (UTMB) runs the “Galveston National Lab,” a high security National Biocontainment Laboratory housing several Biosafety level 4 research laboratories. Known for its abilities to investigate exotic disease diagnosis and research, GLB is one of the 15 biosecurity level 4 facilities in the United States and the largest one in the world located on an academic campus.

With support from the National Institute of Allergy and Infectious Diseases and National Institutes of Health and with a staff of about 300, University of Texas Medical Branch has been active in COVID-19 related research. They help sponsors develop diagnostics, therapeutics and vaccines to combat the most dangerous diseases in the world. The center just recently they received $3.35 million for COVID-19 research from Sealy & Smith Foundation. In April, University of Texas Medical Branch discovered a possible breakthrough genetic system for combatting COVID-19.

Technology Transfer & Startups out of UTMB

UTMB’s Office of Technology Transfer manages the assets of the university research, including the support and nurturing of spinoff startup ventures. They maintain a staff of professionals to engage with industry.

Lead Research/Investigator

Dr. Slobodan Paessler, DVM, PhD, Distinguished University Chair in Biodefense at the University of Texas Medical Branch at Galveston

Call to Action: Interested in doing business with UTMB? Contact their business groups. It would appear that Clyra Medical Technologies could be on to a promising product—perhaps investors are interested?

2 Comments

  1. Colette M.

    It seems that this is a very promising product that could not only be used by our front line workers but also by every person with potential virus exposure especially now that so many states are reopening.

    It would be interesting to know more about the scientists that invented this product as they are the clever ones.

    • TrialSite

      Dear Colette,
      Thanks for visiting! We appreciate.
      We agree. This caught our attention and the National Lab in Galveston is a very serious place.
      The owner of the technology is a small venture hence it will be interesting to see what they do with this.
      A lot of potential given how the virus can hang around surfaces for a few days this could possible take care of that problem.
      Best Regards,
      Publisher

Pin It on Pinterest